

# Susanne Jacobsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10532097/publications.pdf>

Version: 2024-02-01

68  
papers

2,321  
citations

218381

26  
h-index

233125

45  
g-index

68  
all docs

68  
docs citations

68  
times ranked

1817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the incidence of invasive disease due to <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Neisseria meningitidis</i> during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. <i>The Lancet Digital Health</i> , 2021, 3, e360-e370.	5.9	260
2	The novel 2016 WHO reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3096-3108.	1.3	246
3	Public health surveillance of multidrug-resistant clones of <i>Neisseria gonorrhoeae</i> in Europe: a genomic survey. <i>Lancet Infectious Diseases</i> , 2018, 18, 758-768.	4.6	164
4	An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. <i>Eurosurveillance</i> , 2016, 21, .	3.9	98
5	Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in <i>Neisseria gonorrhoeae</i> in 24 European Countries, 2015. <i>BMC Infectious Diseases</i> , 2017, 17, 617.	1.3	90
6	WGS analysis and molecular resistance mechanisms of azithromycin-resistant ( $MIC \geq 2$ ) <i>Neisseria gonorrhoeae</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3109-3116.	1.3	81
7	Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in <i>Neisseria gonorrhoeae</i> in 25 European countries, 2016. <i>BMC Infectious Diseases</i> , 2018, 18, 609.	1.3	69
8	High <i>In Vitro</i> Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant <i>Neisseria gonorrhoeae</i> Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5585-5588.	1.4	62
9	Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	3.9	59
10	Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2281-2286.	1.4	54
11	<i>In vitro</i> activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2072-2077.	1.3	50
12	Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. <i>Vaccine</i> , 2006, 24, 2161-2168.	1.7	49
13	<i>In Vitro</i> Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	48
14	Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. <i>Vaccine</i> , 2009, 27, 1579-1584.	1.7	47
15	WHO laboratory validation of Xpert CT/NG and Xpert TV on the GeneXpert system verifies high performances. <i>Apmis</i> , 2018, 126, 907-912.	0.9	45
16	Genetic Resistance Determinants, <i>In Vitro</i> Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in <i>Neisseria gonorrhoeae</i> . <i>Frontiers in Microbiology</i> , 2015, 6, 1377.	1.5	44
17	Is the tide turning again for cephalosporin resistance in <i>Neisseria gonorrhoeae</i> in Europe? Results from the 2013 European surveillance. <i>BMC Infectious Diseases</i> , 2015, 15, 321.	1.3	44
18	Europe-wide expansion and eradication of multidrug-resistant <i>Neisseria gonorrhoeae</i> lineages: a genomic surveillance study. <i>Lancet Microbe</i> , 2022, 3, e452-e463.	3.4	44

#	ARTICLE	IF	CITATIONS
19	High <i>In Vitro</i> Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical <i>Neisseria gonorrhoeae</i> Isolates from 21 European Countries from 2012 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5220-5225.	1.4	42
20	Direct and Rapid Identification and Genogrouping of Meningococci and <i>porA</i> Amplification by LightCycler PCR. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4531-4535.	1.8	40
21	Meningococcal serogroup Y emergence in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1907-1911.	1.4	35
22	Extensively drug-resistant (XDR) <i>Neisseria gonorrhoeae</i> causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	35
23	<i>Staphylococcus epidermidis</i> surface protein I (SesI): a marker of the invasive capacity of <i>S. epidermidis</i> ?. <i>Journal of Medical Microbiology</i> , 2009, 58, 1395-1397.	0.7	34
24	Whole-Genome Sequencing of Emerging Invasive <i>Neisseria meningitidis</i> Serogroup W in Sweden. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	33
25	Novel meningococcal 4 <sub>CM</sub> vaccine antigens – prevalence and polymorphisms of the encoding genes in <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , 2012, 120, 750-760.	0.9	31
26	High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical <i>Neisseria gonorrhoeae</i> isolates from 25 European countries, 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1221-1228.	1.3	31
27	Meningococcal serogroup Y emergence in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1725-1728.	1.4	29
28	The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for <i>Neisseria gonorrhoeae</i> in the European Union/European Economic Area. <i>BMC Infectious Diseases</i> , 2019, 19, 1040.	1.3	27
29	Genome-Based Characterization of Emergent Invasive <i>Neisseria meningitidis</i> Serogroup Y Isolates in Sweden from 1995 to 2012. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2154-2162.	1.8	25
30	Antimicrobial susceptibility of <i>Neisseria gonorrhoeae</i> isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013–2018. <i>Apmis</i> , 2019, 127, 503-509.	0.9	24
31	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against <i>Neisseria gonorrhoeae</i> in a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 682135.	1.6	23
32	C4BP-IgM protein as a therapeutic approach to treat <i>Neisseria gonorrhoeae</i> infections. <i>JCI Insight</i> , 2019, 4, .	2.3	23
33	Increase of meningococcal serogroup Y cases in Europe: A reason for concern?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 685-688.	1.4	22
34	Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development. <i>Vaccine Journal</i> , 2014, 21, 847-853.	3.2	19
35	In vitro activities of the novel bicyclic modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 173-177.	1.3	17
36	<i>In vitro</i> activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant <i>Neisseria gonorrhoeae</i> isolates. <i>Apmis</i> , 2018, 126, 29-37.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Significant increase in azithromycin resistance and susceptibility to ceftriaxone and cefixime in <i>Neisseria gonorrhoeae</i> isolates in 26 European countries, 2019. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	16
38	Performance characteristics of newer MIC gradient strip tests compared with the Etest for antimicrobial susceptibility testing of <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , 2018, 126, 822-827.	0.9	15
39	Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target CyrB Using a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2022, 13, 874176.	1.6	15
40	Ten years of external quality assessment (EQA) of <i>Neisseria gonorrhoeae</i> antimicrobial susceptibility testing in Europe elucidate high reliability of data. <i>BMC Infectious Diseases</i> , 2019, 19, 281.	1.3	14
41	Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for <i>Neisseria meningitidis</i> . <i>Vaccine</i> , 2009, 27, 5755-5759.	1.7	13
42	In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR <i>Neisseria gonorrhoeae</i> : future treatment option for gonorrhoea?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1591-1594.	1.3	13
43	Genomic epidemiology and antimicrobial resistance determinants of <i>Neisseria gonorrhoeae</i> isolates from Ukraine, 2013–2018. <i>Apmis</i> , 2020, 128, 465-475.	0.9	13
44	Associations between antimicrobial susceptibility/resistance of <i>Neisseria gonorrhoeae</i> isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009–2016. <i>BMC Infectious Diseases</i> , 2021, 21, 273.	1.3	12
45	High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical <i>Neisseria gonorrhoeae</i> Isolates from Thailand and South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
46	Genomic surveillance and antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates in Bangkok, Thailand in 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	11
47	Antimicrobial resistance and <i>Neisseria gonorrhoeae</i> multiantigen sequence typing (NG-MAST) genotypes in <i>N. gonorrhoeae</i> during 2012–2014 in Karachi, Pakistan. <i>BMC Infectious Diseases</i> , 2016, 16, 353.	1.3	10
48	<i>Neisseria meningitidis</i> -Induced Caspase-1 Activation in Human Innate Immune Cells Is LOS-Dependent. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	10
49	Evaluation of the SpeedXResistancePlus®GC and SpeedX GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 84-90.	1.3	10
50	Molecular characterisation of group A <i>Neisseria meningitidis</i> isolated in Sudan 1985-2001. <i>Apmis</i> , 2003, 111, 1060-1066.	0.9	9
51	Characteristics of <i>Neisseria meningitidis</i> isolates causing fatal disease. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 734-744.	1.5	9
52	Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. <i>Journal of Infection</i> , 2020, 81, 575-584.	1.7	9
53	Potential impact of the COVID-19 pandemic on the national and regional incidence, epidemiology and diagnostic testing of chlamydia and gonorrhoea in Sweden, 2020. <i>Apmis</i> , 2022, 130, 34-42.	0.9	9
54	Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009–2019. <i>BMC Infectious Diseases</i> , 2021, 21, 520.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Novel hypercapsulation RNA thermosensor variants in <i>Neisseria meningitidis</i> and their association with invasive meningococcal disease: a genetic and phenotypic investigation and molecular epidemiological study. <i>Lancet Microbe</i> , The, 2020, 1, e319-e327.	3.4	8
56	The European response to control and manage multi- and extensively drug-resistant <i>Neisseria gonorrhoeae</i> . <i>Eurosurveillance</i> , 2022, 27, .	3.9	8
57	Evaluation of molecular typing methods for identification of outbreak-associated <i>Neisseria meningitidis</i> isolates. <i>Apmis</i> , 2013, 121, 503-510.	0.9	6
58	High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines. <i>Vaccine</i> , 2020, 38, 4374-4378.	1.7	6
59	Atypical presentation of <i>Neisseria meningitidis</i> serogroup W disease is associated with the introduction of the 2013 strain. <i>Epidemiology and Infection</i> , 2021, 149, e126.	1.0	6
60	Gene variability and degree of expression of vaccine candidate factor <i>H</i> binding protein in clinical isolates of <i>Neisseria meningitidis</i> . <i>Apmis</i> , 2013, 121, 56-63.	0.9	5
61	<i>Neisseria meningitidis</i> carriage in Swedish teenagers associated with the serogroup W outbreak at the World Scout Jamboree, Japan 2015. <i>Apmis</i> , 2018, 126, 337-341.	0.9	5
62	Antimicrobial resistance and molecular epidemiological typing of <i>Neisseria gonorrhoeae</i> isolates from Kyrgyzstan in Central Asia, 2012 and 2017. <i>BMC Infectious Diseases</i> , 2021, 21, 559.	1.3	4
63	High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3244-3247.	1.3	3
64	In vitro activity of the ketolide cethromycin in multidrug-resistant clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. <i>Journal of Chemotherapy</i> , 2019, 31, 246-251.	0.7	2
65	Despite successful vaccines <i>Neisseria meningitidis</i> strikes again. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1212-1213.	4.6	1
66	Is the Emergence of the <i>N. meningitidis</i> Serogroup W ST-11 Hajj Outbreak Unraveling in the New Era of WGS?. <i>EBioMedicine</i> , 2015, 2, 1294-1295.	2.7	0
67	O01.1...A tale of two halves; low extended-spectrum cephalosporin and high azithromycin resistance in <i>Neisseria gonorrhoeae</i> in Europe, 2015. , 2017, , .		0
68	O03.3...The European gonococcal antimicrobial surveillance programme findings 2017. , 2019, , .		0